IMAX (IMAX) CEO sells 75,919 shares after exercising options under 10b5-1 plan

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

IMAX CORP Chief Executive Officer Richard L. Gelfond exercised stock options and sold the resulting shares in pre-planned trades. On April 16–17, 2026, he converted a total of 75,919 stock options into common shares at $31.40 per share and executed open‑market sales of the same 75,919 common shares at roughly $37.05 per share, pursuant to a Rule 10b5‑1 plan dated December 9, 2025.

Following these transactions, Mr. Gelfond directly holds 765,002 common shares, with additional remaining awards of 1,341,354 outstanding stock options and 231,562 restricted share units. The options exercised were originally granted in 2016 and are scheduled to expire on June 7, 2026, so the activity reflects the use of nearing‑expiration options combined with a pre‑scheduled liquidity event.

Insider Trade Summary 10b5-1

Net Seller: 75,919 shares ($2,813,028)

Net Sell 7 txns

Insider GELFOND RICHARD L

Role Chief Executive Officer

Sold 75,919 shs ($2.81M)

Type	Security	Shares	Price	Value
Conversion	stock options (to buy)	34,182	$31.40	$1.07M
Conversion	common shares	34,182	$31.40	$1.07M
Sale	common shares	34,182	$37.0572	$1.27M
Conversion	stock options (to buy)	41,737	$31.40	$1.31M
Conversion	common shares	41,737	$31.40	$1.31M
Sale	common shares	41,737	$37.0496	$1.55M
holding	common shares (opening balance)	--	--	--

Holdings After Transaction: stock options (to buy) — 1,341,354 shares (Direct, null); common shares — 799,184 shares (Direct, null); common shares (opening balance) — 765,002 shares (Direct, null)

Footnotes (1)

Represents the conversion upon exercise of stock options into common shares pursuant to a 10b5-1 Plan dated December 9, 2025. These options were issued in 2016 and are set to expire on June 7, 2026. The stock options became exercisable in three installments: 162,095 on each of June 7, 2016 and September 1, 2016 and 162,094 on December 31, 2016. This represents the number of common shares for this transaction only. Mr. Gelfond's aggregate remaining outstanding option, restricted share unit and common share balances following these transactions will be 1,341,354, 231,562 and 765,002, respectively.

Key Figures

Shares sold: 75,919 shares Sale prices: $37.0496 and $37.0572 per share Option exercise price: $31.40 per share +5 more

8 metrics

Shares sold 75,919 shares Total common shares sold in open-market transactions on April 16–17, 2026

Sale prices $37.0496 and $37.0572 per share Average sale prices for 41,737 and 34,182 common shares

Option exercise price $31.40 per share Conversion price for 75,919 stock options into common shares

Common shares held 765,002 shares Direct IMAX common share holdings after reported transactions

Outstanding stock options 1,341,354 options Remaining option balance following the April 2026 exercises

Restricted share units 231,562 RSUs Remaining restricted share unit balance after transactions

Option expiration date June 7, 2026 Expiration for the 2016 stock options that were exercised

Net share direction Net sale of 75,919 shares NetBuySellShares from transaction summary showing net-sell activity

Key Terms

Rule 10b5-1 Plan, derivative conversion, stock options (to buy), restricted share unit, +1 more

5 terms

Rule 10b5-1 Plan regulatory

"Represents the conversion upon exercise of stock options into common shares pursuant to a 10b5-1 Plan dated December 9, 2025."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

derivative conversion financial

"transaction_action": "derivative conversion","transaction_code_description": "Conversion of derivative security""

stock options (to buy) financial

""security_title": "stock options (to buy)","conversion_or_exercise_price": "31.4000""

open-market sale financial

""transaction_action": "open-market sale","transaction_code_description": "Sale in open market or private transaction""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

04/20/2026 - 05:46 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GELFOND RICHARD L

(Last)

(First)

(Middle)

902 BROADWAY

20TH FLOOR

(Street)

NEW YORK

10010-6002

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMAX CORP [ IMAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
common shares (opening balance)								765,002	D
common shares	04/16/2026		C		41,737⁽¹⁾	A	$31.4	806,739	D
common shares	04/16/2026		S		41,737	D	$37.0496	765,002	D
common shares	04/17/2026		C		34,182⁽¹⁾	A	$31.4	799,184	D
common shares	04/17/2026		S		34,182	D	$37.0572	765,002	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
stock options (to buy)⁽²⁾	$31.4	04/16/2026		C			41,737	⁽³⁾	06/07/2026	common shares	41,737	$31.4	1,375,536⁽⁴⁾	D
stock options (to buy)⁽²⁾	$31.4	04/17/2026		C			34,182	⁽³⁾	06/07/2026	common shares	34,182	$31.4	1,341,354⁽⁴⁾	D

Explanation of Responses:

1. Represents the conversion upon exercise of stock options into common shares pursuant to a 10b5-1 Plan dated December 9, 2025.

2. These options were issued in 2016 and are set to expire on June 7, 2026.

3. The stock options became exercisable in three installments: 162,095 on each of June 7, 2016 and September 1, 2016 and 162,094 on December 31, 2016.

4. This represents the number of common shares for this transaction only. Mr. Gelfond's aggregate remaining outstanding option, restricted share unit and common share balances following these transactions will be 1,341,354, 231,562 and 765,002, respectively.

Remarks:

	/s/ Richard L. Gelfond	04/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did IMAX (IMAX) CEO Richard Gelfond report?

IMAX CEO Richard Gelfond reported exercising stock options and selling the resulting shares. He converted 75,919 options into common shares and sold the same 75,919 shares in open‑market trades over April 16–17, 2026 under a pre‑planned Rule 10b5‑1 arrangement.

How many IMAX shares did the CEO sell in this Form 4 filing?

Richard Gelfond sold a total of 75,919 IMAX common shares. The sales occurred in two tranches of 41,737 and 34,182 shares at prices around $37.05 per share, immediately after converting an equal number of stock options into common shares.

At what prices did IMAX’s CEO exercise options and sell shares?

The IMAX CEO exercised stock options at a conversion price of $31.40 per share and sold the resulting shares at average prices near $37.05 per share. This reflects an exercise‑and‑sell pattern where options are converted and shares sold soon after exercise.

Were the IMAX CEO’s option exercises and sales pre-planned under Rule 10b5-1?

Yes. The Form 4 footnotes state the option conversions into common shares occurred pursuant to a Rule 10b5‑1 plan dated December 9, 2025. Such plans pre‑schedule trades, indicating the timing of these exercises and sales was set in advance rather than decided opportunistically.

What IMAX equity holdings does CEO Richard Gelfond have after these transactions?

After the reported transactions, Richard Gelfond directly holds 765,002 IMAX common shares, plus 1,341,354 outstanding stock options and 231,562 restricted share units. These figures show he retains substantial exposure to IMAX equity despite the option exercise‑and‑sale sequence reported in this Form 4.

Why were the IMAX CEO’s options exercised now according to the filing?

Footnotes explain the exercised stock options were granted in 2016 and are set to expire on June 7, 2026. Exercising them in April 2026 aligns with approaching expiration, combining contractual timing with a pre‑planned Rule 10b5‑1 trading arrangement for the subsequent share sales.